Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma

Jiangxi Provincial Cancer Hospital

Status: Active, not recruiting

Conditions: Histopathological Diagnosis of Nasopharyngeal Carcinoma; Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition

Study type: Observational

Funder types: Other

Identifiers

NCT06762470

SKJP1320242038

Details and patient eligibility

About

In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma. Building on these findings, this study aims to conduct a multi-center prospective observational study to evaluate the prognostic value of the circulating lymphocyte CD4/CD8 ratio in nasopharyngeal carcinoma patients prior to treatment.

Enrollment: 325 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1.Histopathological diagnosis of nasopharyngeal carcinoma;2.Patients with nasopharyngeal carcinoma without distant metastases after AJCC/UACC 8th edition;3.The radiation therapy technique is IMRT;4.Age 18-70 years;5.Has good organ function;6.Patients who are willing and able to comply with visit schedules, treatment plans, laboratory tests, and other study procedures; 7.Willing to comply with the arrangement during the study period and can no longer participate in any other clinical studies related to drugs and medical devices;8.Patients sign a formal informed consent form to indicate that they understand that this study is in accordance with the hospital's policies.

Exclusion criteria

• 1.Concomitant with other tumors;2.Those with a history of severe immediate allergies to any of the drugs used in this study;3.Lack of or limited capacity for civil conduct;4.Addiction to drugs or alcohol, with a physical or psychiatric disorder;5.Previous diagnosis of immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related disease;6.Pregnant or lactating female patients, male or female patients of childbearing potential who are unwilling or unable to use contraception throughout the study period and for at least 1 year after the end of the treatment regimen.

Trial design

325 participants in 2 patient groups

High CD4/CD8 ratio group

Description:

High CD4/CD8 ratio of peripheral blood lymphocytes before treatment: CD4/CD8 ratio ≥1

Low CD4/CD8 ratio group

Description:

Low CD4/CD8 ratio of peripheral blood lymphocytes before treatment: CD4/CD8 ratio \<1